RxDoctor Payments Data

Charles Kinsey, MD

Pulmonary Disease · Burlington, VTNPI 1871540336

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,663 of the $34,183 with a category attached, or 75.1%. 8 manufacturers reported payments, led by Spiration, Inc. at 48.8% of the total. Among pulmonary disease clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,183in general payments, 2019–2025

Across 61 payments — averaging $560.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spiration, Inc.$17K
  • Janssen Research & Development, LLC$7K
  • Intuitive Surgical$6K
  • Gyrus ACMI, Inc.$3K
  • Johnson & Johnson$863
  • Boston Scientific$600
  • plus $158 from 2 others
$112,803in research payments, 2019–2025

Across 12 payments — averaging $9400.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$74K
  • Spiration, Inc.$22K
  • Gyrus ACMI, Inc.$16K

What the payments were for

  • Consulting fees$25,66375%
  • Travel & lodging$3,76611%
  • Food & beverage$7552%
  • Education$4,00012%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,183 in reported general payments places this provider in the 95th percentile of 25 pulmonary disease providers in Vermont.

See all pulmonary disease providers in Vermont

Medicare billing

Part B allowed, 2024
$41,233
Medicare patients
109
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →